- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01354860
Moxibustion for Knee Osteoarthritis
Moxibustion for Knee Osteoarthritis: a Randomized Pilot Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Knee osteoarthritis (OA) is a common joint disease and a leading cause of pain and physical disability in older people. Its symptoms, including pain and physical disability, significantly affect patient's quality of life, and increased depression has been observed in patients with greater pain due to knee OA. Current management options include exercise, weight reduction, Non-steroidal anti-inflammatory drugs (NSAIDs) and other pain medication, intra-articular injections of steroid or hyaluronan, arthroscopic surgery and joint replacement. Except exercise and weight reduction, no known interventions have shown definitive evidence of benefits and safety for knee OA. Thus, it is still worth exploring effective and safe management options for knee OA patients.
Moxibustion is one of traditional Asian medicine using the heat stimulation by burning mugwort (mainly Artemisia vulgaris or Artemisia argyi) on acupuncture points, and regarded as a subtype of acupuncture. Previous literatures reported its use on chronic conditions including gastrointestinal disease, hypertension, musculoskeletal pain, cancer care, gynecological conditions and stroke rehabilitation solely or in combination with routine care or other traditional medicine. However, studies adequately evaluating effects and safety of moxibustion for patients with knee OA are insufficient. Given the gaps between little evidence for effects and safety of moxibustion for knee osteoarthritis and its wide use in clinical practice, the investigators attempted to assess the feasibility, effectiveness and safety of moxibustion for patients with knee osteoarthritis.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Daejeon, Korea, Republic of
- Daejeon University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged from 40 to 70 years old
- Average daily knee pain over 40 points (0-100 point scale)
- diagnosed as knee osteoarthritis according to ACR criteria
Exclusion Criteria:
- Current of past history of inflammatory disease including rheumatoid arthritis
- Cancer
- Traumatic injury which might be related to current knee pain
- Autoimmune disease
- significant deformity of knee joints
- knee replacement surgery on affected knee
- knee arthroscopy within 2 years
- steroid injection in knee joints within 3 months
- viscosupplement injections in knee joints within 6 months
- joint fluid injection within 6 months
- received acupuncture, moxibustion, cupping or herbal medicine within 4 weeks
- uncontrolled hypertension
- diabetes mellitus requiring insulin injection
- life-threatening cardiovascular or neurological events within one year
- chronic respiratory disease
- hemorrhagic disorder
- alcohol or drug addition
- active infectious disease including tuberculosis
- keloidosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Moxibustion treatment plus usual care
|
Treatment group received moxibustion treatment three times a week for 4 consecutive weeks, totally 12 sessions of treatment in addition to usual care to manage their knee OA. Moxibustion points include six local acupuncture points on affected knee joint. Up to two additional tender points will be allowed, if necessary. If participants feel knee pain on both knee joints, study practitioners will provide treatment on both knee. We will use smokeless indirect moxibustion made of wormwood with a diameter of 1.9 centirmeter and a length of 2.1 centimeter in a cylindrical form for this study (Haitnim Bosung Inc, Korea). Free participant-practitioner interaction will be allowed during the treatment session. Expected total time of each treatment session will be 40 - 60 minutes.
Other Names:
|
NO_INTERVENTION: usual care alone
|
Usual care alone group can receive or use any kind of treatment other than moxibustion treatment provided as study intervention, which includes surgery, conventional medication, physical treatment, acupuncture, herbal medicine, over-the-counter drugs and other active treatment. This also applies to the moxibustion treatment group. Education material of information on knee osteoarthritis and current management option and self-exercise sheet with a yoga-mat to enhance regular exercise will be provided in both groups at baseline. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
knee pain measured by Western Ontario MacMaster (WOMAC) pain subscale
Time Frame: 4 weeks from baseline
|
The primary outcome is the knee pain measured by WOMAC pain subscale at 4 weeks from baseline.
|
4 weeks from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change from baseline to 4, 8 and 12 weeks in the Short Form Health Survey (SF)-36
Time Frame: at base line, 4 ,8 and 12 weeks later after allocation
|
at base line, 4 ,8 and 12 weeks later after allocation
|
|
The change from baseline to 4, 8 and 12 weeks in the Beck Depression Inventory(BDI)
Time Frame: at base line, 4 ,8 and 12 weeks later after allocation
|
at base line, 4 ,8 and 12 weeks later after allocation
|
|
The change from baseline to 4, 8 and 12 weeks in the Patient global assessment
Time Frame: 4 ,8 and 12 weeks later after allocation
|
Practitioners and participants will evaluate the improvement of knee joint symptoms after treatment.
They can chose one of the following 5 grades: Excellent, Good, Fair, Poor and Aggravation.
|
4 ,8 and 12 weeks later after allocation
|
The change from baseline to 4, 8 and 12 weeks in the physical performance test
Time Frame: at a baseline, 4 ,8 and 12 weeks later after allocation
|
Timed-stand test/standing balance test/Six minue walk test
|
at a baseline, 4 ,8 and 12 weeks later after allocation
|
The change from baseline to 4, 8 and 12 weeks in the Numeric Rating Scale (NRS) for pain
Time Frame: at a baseline, 4 ,8 and 12 weeks later after allocation
|
at a baseline, 4 ,8 and 12 weeks later after allocation
|
|
The change from baseline to 4, 8 and 12 weeks in the Safety measurement
Time Frame: at a baseline, 4 ,8 and 12 weeks later after allocation
|
at a baseline, 4 ,8 and 12 weeks later after allocation
|
|
The change from baseline to 4, 8 and 12 weeks in the other WOMAC subscale and global score
Time Frame: at base line, 4 ,8 and 12 weeks later after allocation
|
at base line, 4 ,8 and 12 weeks later after allocation
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Osteoarthritis, Knee
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Respiratory System Agents
- Lobeline
Other Study ID Numbers
- KI1002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Osteoarthritis
-
Asfendiyarov Kazakh National Medical UniversityCompletedIdiopathic OsteoarthritisKazakhstan
-
Werner AnderlActive, not recruitingIdiopathic Osteoarthritis | Posttraumatic Osteoarthritis | Humeral Head Necrosis | Instability Arthritis
-
Sahlgrenska University Hospital, SwedenZimmer BiometActive, not recruitingSurgical Treatment | Primary Hip Osteoarthritis | Secondary Hip Osteoarthritis Due to Idiopathic Femoral Head Necrosis, Childhood or Inflammatory Disease | Bilateral Hip Disease
-
Tel-Aviv Sourasky Medical CenterUnknownIdiopathic FallersIsrael
-
Necmettin Erbakan UniversityCompletedIdiopathic Polyhydramios CasesTurkey
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
Shriners Hospitals for ChildrenRecruitingIdiopathic Toe WalkingUnited States
-
Tel-Aviv Sourasky Medical CenterUnknownElderly Idiopathic FallersUnited States, Israel
-
Mayo ClinicCompleted
-
Karolinska InstitutetCompleted
Clinical Trials on Moxibustion treatment plus usual care
-
University of WashingtonNational Institute of Nursing Research (NINR)Completed
-
Stanford UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedObesity, ChildhoodUnited States
-
Major Extremity Trauma Research ConsortiumCompletedSevere Orthopedic TraumaUnited States
-
Suzanna ZickUniversity of MichiganTerminatedQuality of Life | Fatigue | Lupus Erythematosus, Systemic | Sleep | Pain, ChronicUnited States
-
University of PennsylvaniaNational Cancer Institute (NCI); American Cancer Society, Inc.CompletedFibrosis | Head and Neck Cancer | LymphedemaUnited States
-
Eun Jung KimDongGuk UniversityUnknown
-
Jiangxi University of Traditional Chinese MedicineActive, not recruitingPrimary HypertensionChina
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)CompletedHuman Immunodeficiency Virus | Hepatitis C Virus Infection, Response to Therapy ofUnited States
-
South London and Maudsley NHS Foundation TrustCompletedAttention Deficit Hyperactivity DisorderUnited Kingdom
-
San Diego State UniversityNational Institute of Mental Health (NIMH); Hennepin Healthcare Research InstituteCompleted